{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=n-Lorem+Foundation", "query": { "sponsor": "n-Lorem Foundation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=n-Lorem+Foundation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T07:27:59.617Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07197268", "title": "Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bainbridge-Ropers Syndrome" ], "interventions": [ { "name": "nL-ASXL3-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "4 Years", "sex": "MALE", "summary": "4 Years to 4 Years · Male only" }, "enrollment_count": 1, "start_date": "2025-05-19", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07197268" }, { "nct_id": "NCT07095686", "title": "Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "nL-CHCHD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2024-10-02", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07095686" }, { "nct_id": "NCT07588581", "title": "Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Childhood-Onset Neurodegeneration With Brain Atrophy (CONDBA)" ], "interventions": [ { "name": "nL-UBTF-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2025-02-05", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07588581" }, { "nct_id": "NCT06369974", "title": "Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Genetic Disease" ], "interventions": [ { "name": "Antisense oligonucleotide treatment (ASO)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 1, "start_date": "2024-09-18", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06369974" }, { "nct_id": "NCT07423494", "title": "Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "nL-CHCHD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2026-03", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07423494" }, { "nct_id": "NCT06977451", "title": "Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "nL-CHCHD-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "63 Years", "maximum_age": "63 Years", "sex": "ALL", "summary": "63 Years to 63 Years" }, "enrollment_count": 1, "start_date": "2024-06-24", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06977451" }, { "nct_id": "NCT07703462", "title": "Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)" ], "interventions": [ { "name": "nL-TARDB-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1, "start_date": "2026-12", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07703462" }, { "nct_id": "NCT07743268", "title": "Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)" ], "interventions": [ { "name": "nL-TARDB-006", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 6, "start_date": "2026-02-19", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 2, "location_summary": "St Louis, Missouri • New York, New York", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07743268" }, { "nct_id": "NCT07084311", "title": "Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dentatorubral-Pallidoluysian Atrophy" ], "interventions": [ { "name": "nL-ATN1-002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "29 Years", "maximum_age": "29 Years", "sex": "FEMALE", "summary": "29 Years to 29 Years · Female only" }, "enrollment_count": 1, "start_date": "2024-10-24", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT07084311" }, { "nct_id": "NCT07226297", "title": "Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Charcot-Marie-Tooth Disease Type 2D" ], "interventions": [ { "name": "nL-GARS1-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "n-Lorem Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "FEMALE", "summary": "13 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2025-10-27", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-25T07:27:59.617Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226297" } ] }